Solvias

Solvias is a global contract research organization (CRO) specializing in CMC (Chemistry, Manufacturing, and Controls) analytical services. The company serves 700+ customers worldwide, including 19 of the top 20 pharma companies.

Core Capabilities

Analytical Services:

• Analytical method development and validation
• Analytical characterization services
• cGMP drug substance and drug product testing and release
• Excipient and raw materials testing and release
• Genetic quality control testing
• Extractables and leachables testing
• Stability testing
• Biosafety testing
• Impurity testing and contamination control
• Container closure integrity testing (CCIT)
• Cell-based bioassays

Therapeutic Expertise:

• Biologics: Extensive expertise in analyzing sophisticated large molecule drugs
• Cell & Gene Therapies: Specialized expertise in analysis for next-generation therapies, including genetic characterization and QC of genetically modified cell lines
• Small Molecules: Comprehensive testing capabilities across a wide range of compounds

Organization

Solvias employs 800+ team members across Europe and the U.S., including 175+ PhD-level scientists. The company was founded in 1999 after being spun out from Novartis, with headquarters established in Kaiseraugst, Switzerland in 2011. Recent acquisitions include Confarma (2013), Chemic (2020), and Cergentis (2022) to expand biologics and cell & gene therapy capabilities. In 2025, Solvias opened a Center of Excellence for Biologics and Cell & Gene Therapy in Research Triangle Park.

Commitment

The company emphasizes scientific sophistication, shared commitment to customer success, comprehensive solutions across the development journey, and quality obsession with regulatory-ready deliverables.